Preclinical Bulimia Research Services

Inquiry

Ace Therapeutics is a preclinical contract research and development organization focused on psychiatric disorders. We are dedicated to providing comprehensive solutions for preclinical development of bulimia nervosa. With our advanced disease modeling and platform technologies, we can help our clients to deeply explore the pathological mechanisms of bulimia nervosa and conduct comprehensive efficacy and safety assessments of potential drug candidates. We aim to help you make progress in bulimia-related research and drug development.

Pharmacological Treatment of Bulimia

Pharmacological treatment for bulimia includes antidepressants, anticonvulsants, neuropeptide Y inhibitors, and appetite suppressants.

Antidepressants: Bulimia is often accompanied by depressive symptoms, and antidepressants can improve mood and reduce binge eating episodes.
Anticonvulsants: Certain anticonvulsants can also be used to treat bulimia nervosa.
Neuropeptide Y inhibitors: Neuropeptide Y is a hormone that promotes appetite. Neuropeptide Y inhibitors may decrease appetite and reduce the risk of bulimia attacks.
Appetite suppressants: Appetite suppressants can suppress appetite and reduce the amount of food eaten by people with bulimia.

It is important to note that although these drugs help control episodes of bulimia, they may have little effect on weight loss.

How Can We Help?

Pathophysiology Research Services of Bulimia

Ace Therapeutics employs cutting-edge technology to assist clients in investigating the molecular mechanisms and neural circuits that underlie bulimia nervosa. Our research advances the understanding of bulimia pathogenesis while also providing the scientific basis for the development of targeted diagnostic tools and therapeutic strategies to help our clients make breakthroughs in bulimia research.

Neurochemistry	Patients with bulimia have lower serum concentrations of brain-derived neurotrophic factors, such as insulin-like growth factor-1 and neurotrophic factor. As for neurotransmitters, serum concentrations of 5-hydroxytryptamine were decreased, while dopamine levels were increased. Neurotransmitter imbalance in brain regions may be the cause of appetite disorders.
Electrophysiology	It has been found that the cortical activity of bulimia patients differs from normal individuals, including reduced activity in the prefrontal and parietal cortices and increased activity in the temporal cortex. These changes may be related to the onset and development of bulimia.
Endocrine regulation	Abnormal release of endocrine substances such as gastrointestinal hormones, insulin, gastrin, and glucagon may influence the onset and development of bulimia.
Brain structure	Abnormal structural and functional connections in brain regions such as the cerebral cortex, amygdala, hypothalamus, and ventral prefrontal cortex may be associated with the occurrence and development of bulimia.

Preclinical Screening and Evaluation Services for Bulimia Nervosa Therapeutic drugs

Ace Therapeutics can help you effectively screen and optimize drug molecules to reduce the occurrence of fatal and adverse reactions. In the treatment of bulimia, our preclinical drug development services often involve pharmacology, toxicology, metabolic kinetics, drug safety, and efficacy. We typically collaborate with medical institutions and drug companies to develop and study novel drug molecules. These services will often include screening and evaluating drug properties, determining drug activity and efficacy, and studying the metabolic processes of drugs in animals.

Related Services

Ace Therapeutics' preclinical drug development services can shorten the drug development cycle, reduce risks in drug development, and accelerate drug launch. If you are interested in our services, please contact us to learn how we can support you in your project.

Inquiry

* Name

Phone

* Email

* Services or Products of Interest

Project Description

* Please note that all of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

* Tick to confirm the Research Use Only (RUO) statement.